Open Access
Article
Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges
Madhav V Dhodapkar1
1
Hematology Section, Yale University School of Medicine, New Haven, CT 06510, USA. madhav.dhodapkar@yale.edu
DOI: 10.2741/3278 Volume 14 Issue 3, pp.796-807
Published: 01 January 2009
(This article belongs to the Special Issue Immunotherapy based on innate lymphocytes)
Abstract

Glycolipid reactive CD1d restricted natural killer T (NKT) cells represent a distinct population of T cells implicated in the regulation of immune responses in a broad range of diseases including cancer. Several studies have demonstrated the capacity of NKT cells bearing an invariant T cell receptor (iNKT cells) to recruit both innate and adaptive anti-tumor immunity and mediate tumor rejection in mice. Early phase clinical studies in humans have demonstrated the capacity of dendritic cells (DCs) to mediate expansion of NKT cells in vivo. However several challenges need to be overcome in order to effectively harness the properties of these cells in the clinic.

Share and Cite
Madhav V Dhodapkar. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Frontiers in Bioscience-Landmark. 2009. 14(3); 796-807.